Evolutive profile of ROS levels in BM primitive progenitors and BM antioxidogram in MDS/sAML patients. (Top) Increasing ROS levels in CD34^posCD38^low progenitors during MDS evolution, from healthy controls (low ROS level) to MDS patients (intermediate ROS level), then sAML transformation (high ROS level), according to Figure 1. According to Figure 2, the middle panel shows the evolution of the antioxidogram from healthy controls to MDS with <5% BM blasts, MDS with 5% to 19% BM blasts, and sAML patients, successively. (Bottom) Variations of the antioxidant profile during transitions from MDS with <5% BM blasts to MDS with 5% to 19% BM blasts and sAML. Significant difference (ΔCt values), *P < .05.